BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38755413)

  • 21. Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β.
    Hirayama A; Tanaka K; Tsutsumi H; Nakanishi T; Yamashita S; Mizusaki S; Ishii Y; Ota K; Yoneshima Y; Iwama E; Okamoto I
    Front Immunol; 2023; 14():1192861. PubMed ID: 37441079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment.
    Mimura K; Kua LF; Shiraishi K; Kee Siang L; Shabbir A; Komachi M; Suzuki Y; Nakano T; Yong WP; So J; Kono K
    Cancer Sci; 2014 Oct; 105(10):1236-44. PubMed ID: 25154680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
    Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
    Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leuconostoc mesenteroides-derived anticancer pharmaceuticals hinder inflammation and cell survival in colon cancer cells by modulating NF-κB/AKT/PTEN/MAPK pathways.
    Zununi Vahed S; Barzegari A; Rahbar Saadat Y; Goreyshi A; Omidi Y
    Biomed Pharmacother; 2017 Oct; 94():1094-1100. PubMed ID: 28821160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response.
    Liu L; Hou J; Xu Y; Qin L; Liu W; Zhang H; Li Y; Chen M; Deng M; Zhao B; Hu J; Zheng H; Li C; Meng S
    PLoS One; 2020; 15(7):e0228302. PubMed ID: 32628668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
    Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Propranolol reduces IFN-γ driven PD-L1 immunosuppression and improves anti-tumour immunity in ovarian cancer.
    Falcinelli M; Al-Hity G; Baron S; Mampay M; Allen MC; Samuels M; Jones W; Cilibrasi C; Flaherty RL; Giamas G; Thaker PH; Flint MS
    Brain Behav Immun; 2023 May; 110():1-12. PubMed ID: 36796704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amlexanox enhances the antitumor effect of anti-PD-1 antibody.
    Takeda K; Yano K; Yamada K; Kihara A
    Biochem Biophys Res Commun; 2021 Jun; 560():1-6. PubMed ID: 33965784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
    Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
    Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Escherichia coli K12 Upregulates Programmed Cell Death Ligand 1 (PD-L1) Expression in Gamma Interferon-Sensitized Intestinal Epithelial Cells via the NF-κB Pathway.
    Lee SA; Wang Y; Liu F; Riordan SM; Liu L; Zhang L
    Infect Immun; 2020 Dec; 89(1):. PubMed ID: 33046511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens.
    Iwasaki M; Tanaka Y; Kobayashi H; Murata-Hirai K; Miyabe H; Sugie T; Toi M; Minato N
    Eur J Immunol; 2011 Feb; 41(2):345-55. PubMed ID: 21268005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
    Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
    J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells.
    Li X; Berahovich R; Zhou H; Liu X; Li F; Xu S; Wei Y; Ouaret D; Bodmer W; Wu L; Golubovskaya V
    Front Biosci (Landmark Ed); 2020 Jun; 25(9):1765-1786. PubMed ID: 32472757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.
    Wang X; Yang L; Huang F; Zhang Q; Liu S; Ma L; You Z
    Immunol Lett; 2017 Apr; 184():7-14. PubMed ID: 28223102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.